Please note: Ready Health does not engage an immunologist. Our clinicians have helped many patients start to understand their symptoms and reduce their histamine levels to improve the quality of their lives. We are very happy to see patients who think that they may have these conditions, as there seems to be a distinct absence of understanding of the condition currently.
Specialist private assessment and management for MCAS and histamine-driven conditions. Video appointments across the UK, or in-clinic at our Standish, Wigan practice. One flat fee, inclusive of any prescription charges we issue.
A chronic, multi-system condition where mast cells — part of your immune system — release mediators inappropriately, producing allergic-type symptoms without a clear cause.
Mast cells are specialist immune cells that store granules of histamine, heparin, tryptase, prostaglandins, leukotrienes and many other chemical mediators. They are designed to release these substances when your body encounters a genuine threat such as a virus, bacterium, or injury.
In Mast Cell Activation Syndrome (MCAS), mast cells become chronically over-reactive and release excessive amounts of these mediators in response to ordinary, harmless stimuli — or sometimes with no identifiable trigger at all. Because mast cells are present throughout the body, symptoms can occur anywhere: skin, gut, lungs, cardiovascular system, nervous system, and beyond.
MCAS frequently overlaps with Histamine Intolerance (HIT), Postural Tachycardia Syndrome (PoTS), Hypermobility Spectrum Disorders / hEDS, Long COVID, ME/CFS, and Fibromyalgia. Around one in five people with histamine intolerance also have MCAS, and will not respond fully to diet and antihistamines alone — they will usually need a mast cell stabilising medication as well.
There is no permanent cure, but with careful assessment, trigger identification, and a tailored medication plan, most patients experience meaningful improvement in symptoms and quality of life. We provide honest, practical guidance rooted in the best available UK clinical evidence — read our in-depth guide in our MCAS blog post for further background.
Read our detailed explainer: Mast Cell Activation Syndrome — a UK patient guide →
A chronic disorder of inappropriate mast cell mediator release, producing symptoms that fluctuate in severity and frequently cross multiple body systems.
Because mast cells sit in every tissue of the body, symptoms are diverse, often migratory, and frequently dismissed. Patients typically report episodes that come and go, sometimes daily, sometimes weekly.
Flushing, hives, itching, dermatographism, angioedema, rashes and unexplained welts.
Palpitations, tachycardia, low or labile blood pressure, chest tightness, dizziness, syncope.
Brain fog, migraines, headaches, anxiety, insomnia, paraesthesia, cognitive dysfunction.
Abdominal pain, bloating, nausea, reflux, diarrhoea or constipation, food reactions, IBS-like symptoms.
Nasal congestion, sneezing, throat tightness, wheezing, shortness of breath, chronic cough.
Profound fatigue, malaise, temperature intolerance, unexplained weight change, chronic inflammation.
Joint pain, muscle aches, bone pain, generalised stiffness, exercise intolerance.
Reactions to foods, drugs, insect stings, fragrances or with no identifiable trigger at all.
Avoiding triggers is the essential first step in MCAS management. During your consultation we help you build a personalised trigger profile across all of these categories.
A strict low-histamine diet for four weeks is typically recommended to assess benefit. Useful classifications include the SIGHI (Swiss Interest Group Histamine Intolerance) food list — foods graded 2 and 3 should be avoided first, with H1 and L1 foods removed if needed.
Many prescription drugs inhibit diamine oxidase (DAO) and histamine-N-methyltransferase (HNMT), the enzymes that break histamine down. If you tolerate these without obvious adverse effect, there is usually no need to stop them — but your clinician will review them carefully.
Oestrogen stimulates mast cells and inhibits DAO — so MCAS and histamine intolerance symptoms are often worse around ovulation and before menstruation, and can change significantly during perimenopause, menopause, pregnancy and with hormone therapy.
MCAS management follows a stepwise approach. Your clinician will build a tailored plan, typically starting with H1 and H2 antihistamines and adding mast cell stabilisers or other agents as needed. All prescribing decisions are individualised and reviewed at follow-up.
Block histamine H1 receptors and bring clinically significant benefit to most MCAS patients. Frequently required twice daily rather than once.
Target gastric and systemic H2 receptors. Usually combined with an H1. Twice-daily dosing is typical in MCAS.
Prevent mast cell degranulation at the source. Full benefit can take up to 6 months as mast cells turn over.
Block leukotriene receptors, another important class of mast cell mediators. Useful where respiratory or inflammatory symptoms dominate.
Several supplements have mast cell stabilising or anti-inflammatory effects and can be useful alongside prescribed medication.
Can help some MCAS patients — but may precipitate reactions in a minority. Trial should only ever be under clinical supervision.
Have mast cell stabilising effects in addition to their anxiolytic action. Considered carefully where anxiety is a prominent MCAS feature.
For severe refractory cases. In the UK, omalizumab is only licensed for severe allergic asthma and chronic urticaria and requires specialist referral.
Neural retraining programmes can significantly reduce symptom burden by calming the autonomic nervous system and dampening threat-response patterns that maintain mast cell activation.
There is emerging interest in GLP-1 receptor agonists (e.g. semaglutide, tirzepatide) in MCAS, after some patients treated for obesity or type 2 diabetes reported improvement in mast cell symptoms. A 2025 retrospective study by Dr Lawrence Afrin and colleagues reported clinical benefit in 89% of 47 MCAS cases, though most were overweight or obese.
At present there is insufficient evidence to recommend GLP-1 therapy outside its licensed indications of obesity and type 2 diabetes. The appropriate route for patients interested in this approach is enrolment in a clinical trial. We will discuss the evidence honestly during your consultation.
If you need surgery, please share your MCAS diagnosis with the anaesthetist. Adrenaline-free local anaesthesia is preferred; H1 antihistamines should typically be doubled for two days before and after surgery; and low-dose naltrexone, if you take it, is usually stopped two days before anaesthesia. We can provide a letter for your surgical team.
A clear, unhurried pathway designed around patients who have often been through years of missed diagnoses.
Choose video or in-clinic (Standish, Wigan). Pay the £119 fee at the time of booking to secure your slot.
Complete a detailed symptom, trigger and medication questionnaire so your clinician can prepare in advance.
A thorough 30–45 minute discussion, examination (if in-clinic), tailored plan and any appropriate private prescription.
Written summary of your plan, access to follow-up appointments, and prescription reissue when clinically appropriate.
Select a time that suits you — video consultations are available UK-wide; in-clinic appointments are held at 22 High Street, Standish, Wigan, WN6 0HL.
MCAS is a clinical diagnosis supported by a pattern of recurrent, multi-system allergic-type symptoms affecting at least two organ systems, objective evidence of mast cell mediator release where possible, and a clear response to mast-cell–targeted treatment. There is no single definitive test. Your clinician will take a detailed history and, where helpful, discuss tests such as serum tryptase or 24-hour urinary histamine metabolites.
The fee covers your full consultation (video or in-clinic), assessment, tailored management plan, and any private prescription we issue at that appointment. Medication costs from the pharmacy and any laboratory tests ordered are charged separately.
Yes. We offer secure video consultations UK-wide. In-clinic appointments take place at 22 High Street, Standish, Wigan, WN6 0HL.
No. You can self-refer by booking directly through the booking tool above. With your permission we will write to your GP after the consultation.
Most patients start with H1 and H2 antihistamines (e.g. cetirizine or fexofenadine plus famotidine or nizatidine), often twice daily. Depending on response, we may add mast cell stabilisers such as sodium cromoglicate or ketotifen, or a leukotriene antagonist such as montelukast. Supplements such as quercetin, high-dose vitamin C and vitamin D are often adjuncts. All prescribing is individualised.
Some patients notice improvement within days of starting H1/H2 antihistamines and trigger avoidance. Mast cell stabilisers can take up to six months for full effect, as mast cells turn over slowly. MCAS management is usually a stepwise process with regular review.
No. Ready Health does not engage an immunologist. Our experienced GMC-registered clinicians have helped many patients begin to understand their symptoms and reduce their histamine levels to improve their quality of life. We welcome patients who suspect they may have MCAS, given the widespread lack of understanding of the condition.
Yes. These conditions commonly overlap with MCAS. We take the overlap seriously and will address it as part of your care plan.
Yes. Follow-up consultations can be booked through the same system. Prescription reissue appointments are shorter and lower cost where clinically appropriate.
Private clinics do not provide emergency care. If you are having a severe allergic or anaphylactic reaction, call 999 or go to your nearest A&E immediately. Carry any prescribed adrenaline auto-injectors at all times.
Book a private MCAS consultation with Ready Health — £119, video or in-clinic, prescription inclusive.
Book Now →